Eli Lilly Q1 2026 Earnings: Wall Street’s Expectations and What to Watch

Eli Lilly has become the kind of stock people talk about at dinner parties, even if they’ve never opened a brokerage account. And that’s entirely because of its weight-loss drugs. When a company transforms from a staid pharmaceutical giant into a cultural phenomenon, earnings day becomes a spectacle. On April 30, 2026, before the market opens, Lilly steps into the spotlight again to report its first-quarter results. The question isn’t just whether the numbers are big. It’s whether they’re big enough to justify the narrative. Let’s break down exactly what Wall Street expects, and what really matters beneath the headline figures.

The Numbers: Wall Street’s Consensus for Q1 2026

Let’s start with the cold, hard estimates. The Street is coalescing around some eye-popping figures. Analysts forecast revenues of roughly $17.78 billion, which would represent a 39.7% increase compared to the same quarter a year ago. On the bottom line, the consensus sits at $7.26 per share, a staggering 117.4% jump year-over-year.

Just to put that in perspective: the company generated $19.29 billion in Q4 2025, handily beating expectations with 42.6% growth. So a slight deceleration from that torrid pace is already baked into estimates. The Zacks Consensus Estimate for EPS has actually seen a modest 2.7% upward revision over the past 30 days, which quietly suggests analysts are growing more confident as the report approaches. However, the full-year 2026 earnings consensus has drifted down from $34.37 to $33.59 per share over the past month, hinting at some longer-term caution creeping in.

Mounjaro and Zepbound: The Twin Engines Driving Growth

These two drugs are the heart of the story. Together, Mounjaro (for diabetes) and Zepbound (for obesity) generated roughly 56% of Eli Lilly’s total revenue in 2025, a staggering concentration risk that is also the company’s greatest competitive advantage.

For Q1, the Zacks Consensus Estimate pegs Mounjaro revenue at $7.32 billion and Zepbound at $4.02 billion. The split matters enormously. Mounjaro enjoys stronger diabetes-related pricing power, while Zepbound’s obesity volume makes it more exposed to the pricing pressures that have become a persistent headache. Wall Street will be watching the year-over-year growth rates side by side. If Zepbound’s growth decelerates relative to Mounjaro, on the same tirzepatide molecule, it signals that the obesity pricing thesis is under more pressure than the buy-side has modeled.

International expansion is the wildcard. Mounjaro sales are surging in markets like India, while the UK list price was raised by up to 170% last year as Lilly navigates shifting U.S. drug pricing policies. The ex-U.S. component of GLP-1 sales is probably being underestimated by consensus models.

Foundayo: The Oral GLP-1 That Won’t Show Up (But Everyone Will Ask About)

Here’s the twist that makes this earnings call particularly fascinating. On April 1, 2026, the FDA approved Lilly’s Foundayo (orforglipron), the only oral GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. Shipments began April 6. But Q1 ended March 31. So Foundayo contributed exactly zero dollars to first-quarter results. And yet, it will dominate the conversation.

Wall Street is intensely curious, and frankly, a little anxious, about Foundayo’s early launch trajectory. Initial prescription data showed 3,707 U.S. prescriptions in its second week, compared to 18,410 for Novo Nordisk’s oral Wegovy at the same point post-launch. That gap spooked the market; Lilly shares slid roughly 3.7% on the Friday before earnings.

But here’s some necessary context: two weeks of data tells you almost nothing definitive. BMO Capital Markets analyst Evan Seigerman put it bluntly: “We’re two weeks into the launch, so it is really too early in my view to make a concrete call on the strength of the launch”. Also, early prescription data may not capture direct-to-consumer sales channels. Analysts generally want five to six weeks of data before drawing conclusions.

What investors will actually be listening for on the conference call is CEO Dave Ricks’ tone. A confident, matter-of-fact framing could settle nerves, even if the early numbers look soft on paper.

Beyond GLP-1s: The "Post-Blockbuster" Pipeline

While everyone’s staring at weight-loss pills, Lilly is quietly building something arguably more important: a pipeline designed to thrive after the GLP-1 gold rush matures. The company spent $2.3 billion acquiring Ajax Therapeutics for next-generation cancer therapies and committed up to $7 billion for Kelonia Therapeutics, which is developing CAR-T therapies that can be generated inside the body. That’s a fundamentally different approach to cell therapy, one that could unlock treatment for far more patients than traditional CAR-T ever could.

Then there’s eloralintide, a novel amylin analog that Leerink Partners analyst David Risinger calls a potential “game-changer” capable of breaking the competitive deadlock in obesity treatment. And on the policy front, Medicare coverage of obesity drugs beginning July 2026 could dramatically expand the addressable market for both Mounjaro and Zepbound. These aren’t just pipeline filler, they’re the building blocks of the next decade’s growth story.

What It Means for LLY Stock: Buy, Sell, or Hold?

Lilly shares have actually declined about 1.5% over the past month while the broader pharmaceutical sector has gained about 10.8% on average. That’s a notable divergence. The stock is hovering near a technical support zone between $825–$912, a level that has sparked meaningful rebounds three times in the past two years. The average peak return from those bounces? 17.5%.

Wall Street remains overwhelmingly constructive. Of 19 analysts covering the stock, 16 rate it a Buy, with an average price target hovering around $1,247–$1,300, implying roughly 40% upside from pre-earnings levels. Bernstein has a $1,300 target and believes Lilly could beat Q1 expectations and raise full-year guidance. Morningstar is more measured, calling shares fairly valued at $870 based on long-term intrinsic value.

The setup is binary: a beat with raised guidance likely ignites the overdue catch-up rally. A miss, or lukewarm Foundayo commentary, could test that support zone in a hurry.

Eli Lilly’s first-quarter 2026 results are about much more than just one set of financials. They represent a crossroads moment for a company whose stock market identity has become inextricably tied to the GLP-1 revolution. The numbers will almost certainly be strong, demand for Mounjaro and Zepbound remains extraordinary. The real question is whether the story has enough momentum to survive the inevitable shift from injectable dominance to an oral-pill battleground, from U.S. pricing power to global expansion economics, and from a single-franchise dependency to a diversified pipeline narrative. That’s what makes Thursday morning so compelling.